These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20715095)

  • 1. Glycolaldehyde-modified β-lactoglobulin AGEs are unable to stimulate inflammatory signaling pathways in RAGE-expressing human cell lines.
    Buetler TM; Latado H; Leclerc E; Weigle B; Baumeyer A; Heizmann CW; Scholz G
    Mol Nutr Food Res; 2011 Feb; 55(2):291-9. PubMed ID: 20715095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N(epsilon)-carboxymethyllysine-modified proteins are unable to bind to RAGE and activate an inflammatory response.
    Buetler TM; Leclerc E; Baumeyer A; Latado H; Newell J; Adolfsson O; Parisod V; Richoz J; Maurer S; Foata F; Piguet D; Junod S; Heizmann CW; Delatour T
    Mol Nutr Food Res; 2008 Mar; 52(3):370-8. PubMed ID: 18320574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs.
    Thornalley PJ
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1013-23. PubMed ID: 9846883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
    Yan SF; Ramasamy R; Schmidt AM
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone.
    Kume S; Kato S; Yamagishi S; Inagaki Y; Ueda S; Arima N; Okawa T; Kojiro M; Nagata K
    J Bone Miner Res; 2005 Sep; 20(9):1647-58. PubMed ID: 16059636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation in receptor for advanced glycation end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro.
    Yoshida T; Park JS; Yokosuka K; Jimbo K; Yamada K; Sato K; Takeuchi M; Yamagishi S; Nagata K
    Spine (Phila Pa 1976); 2009 Jul; 34(15):1544-8. PubMed ID: 19564763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin.
    Mahajan N; Bahl A; Dhawan V
    Int J Cardiol; 2010 Jul; 142(3):273-8. PubMed ID: 19201044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycolaldehyde-derived advanced glycation end products (glycol-AGEs)-induced vascular smooth muscle cell dysfunction is regulated by the AGES-receptor (RAGE) axis in endothelium.
    Nam MH; Son WR; Lee YS; Lee KW
    Cell Commun Adhes; 2015; 22(2-6):67-78. PubMed ID: 27602595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
    Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
    Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLC/CAMK IV-NF-kappaB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells.
    You J; Peng W; Lin X; Huang QL; Lin JY
    Mol Cell Endocrinol; 2010 May; 320(1-2):111-7. PubMed ID: 20171262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.
    Yan SF; Ramasamy R; Naka Y; Schmidt AM
    Circ Res; 2003 Dec; 93(12):1159-69. PubMed ID: 14670831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).
    van Beijnum JR; Buurman WA; Griffioen AW
    Angiogenesis; 2008; 11(1):91-9. PubMed ID: 18264787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.
    Ramasamy R; Yan SF; Schmidt AM
    J Leukoc Biol; 2009 Sep; 86(3):505-12. PubMed ID: 19477910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RAGE, vascular tone and vascular disease.
    Farmer DG; Kennedy S
    Pharmacol Ther; 2009 Nov; 124(2):185-94. PubMed ID: 19616578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond.
    Ramasamy R; Yan SF; Schmidt AM
    Trends Cardiovasc Med; 2005 Oct; 15(7):237-43. PubMed ID: 16226677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation endproducts and their pathogenic roles in neurological disorders.
    Münch G; Westcott B; Menini T; Gugliucci A
    Amino Acids; 2012 Apr; 42(4):1221-36. PubMed ID: 20949363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end-products activate extracellular signal-regulated kinase via the oxidative stress-EGF receptor pathway in renal fibroblasts.
    Chen SC; Guh JY; Hwang CC; Chiou SJ; Lin TD; Ko YM; Huang JS; Yang YL; Chuang LY
    J Cell Biochem; 2010 Jan; 109(1):38-48. PubMed ID: 19885844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK.
    Tanikawa T; Okada Y; Tanikawa R; Tanaka Y
    J Vasc Res; 2009; 46(6):572-80. PubMed ID: 19571577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs).
    Collison KS; Parhar RS; Saleh SS; Meyer BF; Kwaasi AA; Hammami MM; Schmidt AM; Stern DM; Al-Mohanna FA
    J Leukoc Biol; 2002 Mar; 71(3):433-44. PubMed ID: 11867681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAGE in inflammation: a new therapeutic target?
    Bierhaus A; Stern DM; Nawroth PP
    Curr Opin Investig Drugs; 2006 Nov; 7(11):985-91. PubMed ID: 17117586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.